TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20008225
Drug: New and
Normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 27 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 50 mg in 1 mL TOPICAL LOTION [Loreal Paris Age Perfect Rosy Tone SPF 30 Renew and revive healthy tone Visibly younger-looking skin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: New and targeted agents
Study: 17307760
Drug: Congruent odor
Normalized name: Odor Eaters
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Congruent odor (e.g., strawberry/sweet)
Study: 17307760
Drug: Incongruent odor
Normalized name: Odor Eaters
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Incongruent odor (e.g., strawberry/sour)
Study: 15568526
Drug: Sequential Circumferential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Circumferential Compression Device (SCD)
Study: 9347373
Drug: Intratracheal furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratracheal furosemide (0.5 mg/kg)
Study: 8478839
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both (n = 10)
Study: 29329559
Drug: Structured process
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured process to simplify medication administration using the Medication Regimen Simplification Guide for Residential Aged Care.
Study: 10533448
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy after curative resection
Study: 15278664
Drug: Vecuronium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.1 mg.kg(‐1)
Study: 15278664
Drug: Vecuronium 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.2 mg.kg(‐1)
Study: 6628500
Drug: Moclobemide 100
Normalized name: moclobemide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide 100 mg
Study: 12665046
Drug: Moclobemide 150
Normalized name: moclobemide 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide 150 mg
Study: 6628500
Drug: Chronic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic treatment with optimal therapeutic dose (100-400 mg)
Study: 30680643
Drug: Proprioceptive Neuromuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proprioceptive Neuromuscular Facilitation (PNF) treatment
Study: 30680643
Drug: Positioning treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positioning treatment (control)
Study: 27391237
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy (20 weeks of manualized therapy)
Study: 23402870
Drug: γ-tocopherol (γT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: γ-tocopherol (γT) treatment
Study: 23402870
Drug: Placebo (sunflower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sunflower oil capsule)
Study: 11978685
Drug: Biphasic human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic human insulin 30 (BHI 30)
Study: 18370539
Drug: Imiquimod 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 1% cream
Study: 6896301
Drug: AVC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVC plus tamoxifen (Adriamycin 40 mg/m2 i.v., vincristin 1 mg/m2 i.v. on day 1, cyclophosphamide 200 mg/m2 p.o. on days 3-6, and tamoxifen 20 mg twice daily)
Study: 6896301
Drug: AVC (Adriamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVC (Adriamycin 40 mg/m2 i.v., vincristin 1 mg/m2 i.v. on day 1, cyclophosphamide 200 mg/m2 p.o. on days 3-6)
Study: 30587515
Drug: Non-users of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-users of aspirin
Study: 30185394
Drug: BZF961 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: BZF961 500 mg BID for 3 days
Study: 30185394
Drug: BZF961 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: BZF961 50 mg QD or BID with ritonavir
Study: 30185394
Drug: BZF961 lower-dose
Normalized name: Calendula Flower
DrugBank: Calendula officinalis flower (DB14263)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BZF961 lower-dose regimens
Study: 25286175
Drug: CIT-S (Culturally
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIT-S (Culturally Informed Therapy for Schizophrenia), 15 sessions
Study: 20044810
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose ursodeoxycholic acid
Study: 3533087
Drug: Suprofen 300
Normalized name: Suprofen
DrugBank: Suprofen (DB00870)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suprofen 300 mg suppositories, rectally, t.i.d., for 10 days
Study: 26496648
Drug: Paromomycin Intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paromomycin Intramuscular Injection (PMIM) at 11 mg/kg once daily for 21 days
Study: 26496648
Drug: Paromomycin Intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paromomycin Intramuscular Injection (PMIM)
Study: 21852344
Drug: Modified 'You
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified 'You Make the Difference' programme over six weekly sessions
Study: 20027367
Drug: Tenoten (anxiolytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoten (anxiolytic preparation)
Study: 11454075
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (ND) 100 mg/fortnight
Study: 11454075
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (MA) 400 mg/day
Study: 25646326
Drug: Low α-tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low α-tocopherol (<12.0 μmol/L)
Study: 25646326
Drug: Low γ-tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low γ-tocopherol (<0.81 μmol/L)
Study: 17225981
Drug: Low-dose IL-2
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IL-2 treatment
Study: 17225981
Drug: Control (surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (surgery without treatment)
Study: 15129930
Drug: Low carbohydrate
Normalized name: Low carbohydrate beer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low carbohydrate diet (L-CHO)
Study: 11411657
Drug: rhuEPO therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhuEPO therapy
Study: 7985596
Drug: OPC-18790 (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC-18790 (mean dose 5.9 +/- 3.5 mg)
Study: 2465533
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous morphine infusion (5-48 mg, median 19 mg daily)
Study: 2465533
Drug: Conventional intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional intermittent oral or subcutaneous morphine application (10-90 mg, median 50 mg daily)
Study: 2465533
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous morphine infusion
Study: 2465533
Drug: Long-term continuous
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term continuous subcutaneous morphine infusion
Study: 28185141
Drug: Faster aspart
Normalized name: aspartate
DrugBank: Potassium aspartate (DB15819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faster aspart (0.2 U/kg) administered subcutaneously in the abdomen
Study: 28185141
Drug: Faster aspart
Normalized name: aspartate
DrugBank: Potassium aspartate (DB15819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faster aspart (0.2 U/kg) administered subcutaneously in the upper arm
Study: 28185141
Drug: Faster aspart
Normalized name: aspartate
DrugBank: Potassium aspartate (DB15819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faster aspart (0.2 U/kg) administered subcutaneously in the thigh
Study: 28185141
Drug: Faster aspart
Normalized name: aspartate
DrugBank: Potassium aspartate (DB15819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faster aspart (0.02 U/kg) administered intravenously
Study: 23047989
Drug: Acetaminophen (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (15 mg/kg [160 mg/mL])
Study: 21778605
Drug: Acetone+Bonding agent
Normalized name: Acetone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetone+Bonding agent
Study: 21778605
Drug: Silane+Bonding agent
Normalized name: silane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silane+Bonding agent
Study: 16426088
Drug: Antidepressant exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant exposure (initiation or dose increase)
Study: 16426088
Drug: Antidepressant exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant exposure (initiation)
Study: 16426088
Drug: Increased antidepressant
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased antidepressant exposure
Study: 15010373
Drug: High-dose interferon-alfa
Normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon-alfa (5 MIU/m(2) daily)
Study: 15010373
Drug: Low-dose interferon-alfa
Normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose interferon-alfa (3 MIU, 5 times a week)
Study: 9139661
Drug: Three-drug treatment
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug treatment with viral protease and reverse transcriptase inhibitors
Study: 1662579
Drug: Vitamin C,
Normalized name: Vitamin C, sodium salt
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C, thiopronine, and glutathione at a dose of 12 mmol
Study: 7037156
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with methyl‐CCNU and 5‐FU
Study: 14742344
Drug: Group H
Normalized name: Prostaglandin group H
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group H (hypnotic anaesthesia) with propofol effect-site concentration maintained at 2.4 microg x ml(‐1)
Study: 14742344
Drug: Group O
Normalized name: plasma, human, blood group O
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group O (opioid anaesthesia) with propofol effect-site concentration maintained at 1.2 microg x ml(‐1)
Study: 11356779
Drug: Testosterone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (200 mg im weekly)
Study: 9578508
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) treatment at a dose of 9.5 microg/kg, administered subcutaneously every evening
Study: 17023701
Drug: Sterol Bev
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterol Bev (orange juice with 1 g plant sterols per 240 mL, twice a day for 8 weeks)
Study: 17023701
Drug: Placebo Bev
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Bev (reduced-calorie orange juice without plant sterols, twice a day for 8 weeks)
Study: 15124555
Drug: Standard whole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard whole breast irradiation followed by a tumor bed booster dose
Study: 10952094
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg isoflavones/kg body weight/day (65 mg/day)
Study: 10952094
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg isoflavones/kg body weight/day (132 mg/day)
Study: 10952094
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg isoflavones/kg body weight/day (control diet)
Study: 29800546
Drug: Eradication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication therapy (oral omeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg twice daily for a week)
Study: 29800546
Drug: No H
Normalized name: Leader No Hurt Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: No H pylori treatment (control group)
Study: 24491077
Drug: Systemic Behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic Behavior Family Therapy (SBFT)
Study: 14744173
Drug: Nondirective Supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nondirective Supportive Therapy (NST)
Study: 21443815
Drug: Higher-dose DHA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose DHA (approximately 1 % dietary fatty acids)
Study: 21443815
Drug: Higher-dose DHA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose DHA
Study: 17190110
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (200 mg/d ellagic acid)
Study: 17190110
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (100 mg/d ellagic acid)
Study: 17190110
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 mg/d ellagic acid: placebo)
Study: 8706775
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg daily for 2 weeks
Study: 8719186
Drug: Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine infusion (0.1 microgram.kg‐1.min‐1) in groups 2 and 4 (each n = 10)
Study: 6367888
Drug: Sulphamethoxazole‐trimethoprim (SMX‐TMP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphamethoxazole‐trimethoprim (SMX‐TMP) (sulphamethoxazole 1600 mg plus trimethoprim 320 mg) four tablets twice daily for two days
Study: 31055791
Drug: Mycophenolic acid
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mycophenolic acid (1.4 ± 0.5 g/day, as mycophenolate mofetil)
Study: 31055791
Drug: Tacrolimus (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus (5 ± 3 mg/day, immediate release)
Study: 24639106
Drug: Epidural butorphanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural butorphanol (1 mg loading dose followed by 48-h infusion of 0.004 % butorphanol with 0.1 % bupivacaine at 2 mL/h)
Study: 24639106
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline combined with bupivacaine (saline loading dose and 0.1 % bupivacaine infusion at 2 mL/h)
Study: 24021938
Drug: Guided breathing
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided breathing (12-min sessions daily for 8 weeks)
Study: 24021938
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care alone (including non-pharmacological and pharmacological treatment)
Study: 12610036
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (ALA) 600 mg, infused daily intravenously for 5 days/week for 14 treatments
Study: 12610036
Drug: Placebo, infused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, infused daily intravenously for 5 days/week for 14 treatments
Study: 25443384
Drug: TXA irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA irrigation with normal saline (1 mg/mL)
Study: 25421903
Drug: Nasal oxygen
Normalized name: TUBE,NASAL OXYGEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal oxygen therapy
Study: 8370131
Drug: Melatonin 2
Normalized name: melatonin 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 2 mg administered at 1600 and 2000 h
Study: 3529744
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy only (group B)
Study: 3529744
Drug: Plasmaexchange therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasmaexchange therapy
Study: 31678222
Drug: Robot-assisted arm
Normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted arm therapy and hand functional electrical stimulation (RAT+FES)
Study: 31678222
Drug: Intensive conventional
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive conventional therapy
Study: 22894640
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (640 mg t.i.d during chemotherapy with paclitaxel and one month after)
Study: 16371893
Drug: Usual primary
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual primary healthcare treatment
Study: 12208703
Drug: Conventional systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional systemic medical therapy
Study: 10342702
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of measles vaccine at 6 and 9 months
Study: 10342702
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of inactivated polio vaccine (IPV) at 6 months and measles vaccine at 9 months
Study: 10766581
Drug: Azithromycin (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (1200 mg weekly)
Study: 8676932
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs (Rifabutin and Azithromycin)
Study: 28186425
Drug: Oral tramadol/propofol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tramadol/propofol fast (GOF)
Study: 28186425
Drug: Oral tramadol/propofol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tramadol/propofol slow (GOS)
Study: 22009806
Drug: Preoperative antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative antibiotic prophylaxis administered before TUL
Study: 22009806
Drug: TUL without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TUL without antibiotic prophylaxis
Study: 19571807
Drug: CYP2C9 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP2C9 and VKORC1 genotype-guided dosing
Study: 19571807
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard dosing without genotype guidance)
Study: 1926232
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (acetylsalicylic acid and dipyridamole)
Study: 6861867
Drug: Sotalol 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol 100 mg intravenously
Study: 6861867
Drug: Sotalol 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol 400 mg orally
Study: 30879998
Drug: 0.37 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.37 μg of Alt a 1
Study: 30879998
Drug: 0.2 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 μg of Alt a 1
Study: 24780066
Drug: Low-dose glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose glucose (0.1 g/kg/h for 1 h followed by 0.05 g/kg/h for 1 h)
Study: 24780066
Drug: Low-dose glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose glucose (LG group)
Study: 23062390
Drug: Preseasonal grass
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preseasonal grass pollen immunotherapy
Study: 19453867
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health education program (4-month duration)
Study: 15898864
Drug: Cognitive-behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavior therapy for insomnia during discontinuation
Study: 15898864
Drug: No cognitive-behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: No cognitive-behavior therapy for insomnia during discontinuation
Study: 9819068
Drug: Cortisol 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol 40 mg/d
Study: 9819068
Drug: Cortisol 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol 160 mg/d
Study: 8836591
Drug: 5-hydroxy-L-tryptophan (L-5-HTP)
Normalized name: 5-hydroxy-L-tryptophan
DrugBank: Oxitriptan (DB02959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-hydroxy-L-tryptophan (L-5-HTP) plus carbidopa
Study: 3308389
Drug: L-5-HTP
Normalized name: L-5-HTP
DrugBank: Oxitriptan (DB02959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-5-HTP
Study: 2694344
Drug: Furazolidone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furazolidone (5 mg/kg/day for 5 days)
Study: 3054035
Drug: Ampicillin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin (100 mg/kg/day for 5 days)
Study: 22013799
Drug: Blank control
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blank control group (no treatment)
Study: 26681020
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg clopidogrel (test preparation)
Study: 26681020
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg clopidogrel (reference preparation)
Study: 26681020
Drug: Relative bioavailability
Normalized name: (2R*,3S)-rel-1,2,3,4-butanetetroltetranitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relative bioavailability of the test preparation
Study: 23059649
Drug: Baseline serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline serum 25D <50.0 nmol/L in 50% of subjects
Study: 22136021
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Fugui Gutong capsule (3 times a day, 4 capsules each time) and 0.3 g ibuprofen (once a day)
Study: 19891770
Drug: Low-dose adenosine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose adenosine infusion
Study: 9456291
Drug: Nifedipine capsules
Normalized name: Nifedipine Capsules
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine capsules (10 mg, two administrations 6 hours apart)
Study: 9456291
Drug: Nifedipine-retard (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine-retard (20 mg tablets, single administration)
Study: 2576717
Drug: Vecuronium 'high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 'high dose' group (250 micrograms.kg‐1)
Study: 2576717
Drug: Succinylcholine group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine group (1 mg.kg‐1)
Study: 6794587
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg flurazepam
Study: 27633643
Drug: Enhanced Usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced Usual Care (EUC): a manualised consultation with a child and adolescent psychiatrist and individualised treatment plan
Study: 27633643
Drug: Group-based Acceptance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based Acceptance and Commitment Therapy (ACT) plus Enhanced Usual Care (EUC)